Adagene, Inc.
NASDAQ:
ADAG
Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
PricewaterhouseCoopers Zhong Tian LLP
IPO (February 9, 2021)
Cayman Islands
Jiangsu, China
Raymond Tam, Internal
86-8777-3626
Analyst Coverage
Latest News
September 3, 2021: Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference – Adagene Inc.
July 7, 2021: Adagene Announces Authorization of Share Repurchase Program up to US$20 Million – Adagene Inc.
June 16, 2021: Adagene Announces Inclusion in FTSE Russell Indexes – Adagene Inc.
May 25, 2021: Adagene to Present at Upcoming Investor Conferences – Adagene Inc.
March 31, 2021: Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
March 29, 2021: Adagene Announces Clinical Advancement for ADG116
March 16, 2021: Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
February 11, 2021: Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option
February 9, 2021: Adagene Inc. Announces Pricing of Initial Public Offering
January 12, 2021: Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health